Wells Fargo
SVA

Wells Fargo’s Sinovac Biotech, Ltd SVA Stock Holding History

Wells Fargo’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.1K Sell
4,811
-12,065
-71% -$78.1K ﹤0.01% 5618
2025
Q4 		$109K Hold
16,876
– – ﹤0.01% 5360
2025
Q3 		$109K Buy
16,876
+25
+0.1% +$162 ﹤0.01% 5273
2025
Q2 		$109K Buy
+16,851
New +$109K ﹤0.01% 5137
2024
Q3 		– Sell
-12,450
Closed -$80.6K – 7190
2024
Q2 		$80.6K Sell
12,450
-300
-2% -$1.94K ﹤0.01% 5070
2024
Q1 		$82.5K Buy
+12,750
New +$82.5K ﹤0.01% 5006
2023
Q4 		– Sell
-1,661
Closed -$10.7K – 7878
2023
Q3 		$10.7K Hold
1,661
– – ﹤0.01% 5790
2023
Q2 		$10.7K Buy
+1,661
New +$10.7K ﹤0.01% 5892
2022
Q4 		– Sell
-1,687
Closed -$11K – 7970
2022
Q3 		$11K Sell
1,687
-1,250
-43% -$8.15K ﹤0.01% 5673
2022
Q2 		$19K Buy
+2,937
New +$19K ﹤0.01% 5497
2022
Q1 		– Sell
-1,912
Closed – – 8406
2021
Q4 		$0 Hold
1,912
– – ﹤0.01% 8365
2021
Q3 		$19K Hold
1,912
– – ﹤0.01% 6005
2021
Q2 		$0 Sell
1,912
-10
-0.5% – ﹤0.01% 7964
2021
Q1 		$0 Sell
1,922
-1
-0.1% – ﹤0.01% 7824
2020
Q4 		$0 Buy
1,923
+301
+19% – ﹤0.01% 7497
2020
Q3 		$0 Sell
1,622
-979
-38% – ﹤0.01% 7391
2020
Q2 		$0 Buy
2,601
+350
+16% – ﹤0.01% 7312
2020
Q1 		$0 Sell
2,251
-1,763
-44% – ﹤0.01% 7361
2019
Q4 		$0 Hold
4,014
– – ﹤0.01% 7102
2019
Q3 		$0 Buy
4,014
+1
+0% – ﹤0.01% 7063
2019
Q2 		$0 Buy
4,013
+2,763
+221% – ﹤0.01% 6904
2019
Q1 		$8K Hold
1,250
– – ﹤0.01% 5683
2018
Q4 		$9K Hold
1,250
– – ﹤0.01% 5971
2018
Q3 		$10K Hold
1,250
– – ﹤0.01% 6006
2018
Q2 		$9K Hold
1,250
– – ﹤0.01% 5995
2018
Q1 		$11K Hold
1,250
– – ﹤0.01% 5939
2017
Q4 		$10K Hold
1,250
– – ﹤0.01% 5937
2017
Q3 		$9K Hold
1,250
– – ﹤0.01% 5916
2017
Q2 		$8K Hold
1,250
– – ﹤0.01% 5841
2017
Q1 		$7K Hold
1,250
– – ﹤0.01% 5979
2016
Q4 		$7K Hold
1,250
– – ﹤0.01% 5903
2016
Q3 		$7K Hold
1,250
– – ﹤0.01% 5856
2016
Q2 		$7K Sell
1,250
-150
-11% -$919 ﹤0.01% 5767
2016
Q1 		$9K Sell
1,400
-837
-37% -$5.03K ﹤0.01% 5751
2015
Q4 		$13K Sell
2,237
-1,324
-37% -$7.13K ﹤0.01% 5693
2015
Q3 		$18K Buy
3,561
+2,311
+185% +$12.2K ﹤0.01% 5581
2015
Q2 		$7K Sell
1,250
-4,080
-77% -$21.6K ﹤0.01% 5941
2015
Q1 		$26K Hold
5,330
– – ﹤0.01% 5291
2014
Q4 		$28K Buy
5,330
+500
+10% +$2.55K ﹤0.01% 5243
2014
Q3 		$24K Hold
4,830
– – ﹤0.01% 5229
2014
Q2 		$27K Buy
4,830
+4,080
+544% +$24.8K ﹤0.01% 5251
2014
Q1 		$5K Hold
750
– – ﹤0.01% 5576
2013
Q4 		$5K Hold
750
– – ﹤0.01% 5401
2013
Q3 		$4K Hold
750
– – ﹤0.01% 5372
2013
Q2 		$3K Buy
+750
New +$2.79K ﹤0.01% 5355

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Wells Fargo's SVA Position: Q1 2026 in Review

Wells Fargo reduced its Sinovac Biotech, Ltd (SVA) stake by 71% in Q1 2026, selling an estimated $78.1K and leaving 4,811 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5618.

Wells Fargo first reported a position in SVA in Q2 2013 and has held it in 45 quarters since. The position peaked at $109K in Q4 2025. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Wells Fargo held 4,811 shares of Sinovac Biotech, Ltd worth $31.1K as of Q1 2026.
  • Wells Fargo sold 12,065 Sinovac Biotech, Ltd shares in Q1 2026, an estimated $78.1K.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5618 holding.
  • Wells Fargo first reported a position in Sinovac Biotech, Ltd in Q2 2013 and has held it in 45 quarters since.
  • Wells Fargo's Sinovac Biotech, Ltd position peaked at $109K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.